Combined with a comprehensive literature research for recurrent gene abnormalities in MDS [20-22, 27], especially for genes associated with prognosis, we generated a final candidate panel comprsing 11 genes (EZH2, TET2, ASXL1, TP53, DNMT3A, RUNX1, ETV6, SRSF2, U2AF1, IDH1, IDH2) for targeted sequencing in MDS. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.